Enteropathy-associated T-cell lymphoma

  • Dec 10, 2018 lymphomahub.com
    Rituximab-abbs (Truxima®) approved by the FDA for the treatment of CD20-positive B-cell NHL adult patients – Lymphoma Hub
    Read More
  • Dec 10, 2018 lymphomahub.com
    CLARITY phase II trial on ibrutinib and venetoclax combo in R/R CLL – Lymphoma Hub
    Read More
  • Dec 10, 2018 amlglobalportal.com
    Randomized phase II study comparing 5-day and 10-day decitabine schedule in newly diagnosed acute myeloid leukemia – oral abstract presented at ASH 2018 – AML Global Portal
    Read More
  • Dec 06, 2018 www.targetedonc.com
    Brentuximab Vedotin Demonstrates Survival Benefit Over CHOP in CD30+ PTCL – Targeted Oncology
    Read More
  • Dec 05, 2018 www.onclive.com
    Update Details Brentuximab Vedotin Survival Benefit in CD30+ PTCL – OncLive
    Read More
  • Nov 22, 2018 amlglobalportal.com
    Venetoclax (Venclexta®) granted approval by the FDA for the treatment of newly diagnosed acute myeloid leukemia – AML Global Portal
    Read More
  • Nov 16, 2018 lymphomahub.com
    Brentuximab vedotin (Adcetris®) granted Breakthrough Designation Therapy by the FDA for frontline PTCL – Lymphoma Hub
    Read More
  • Nov 02, 2018 lymphomahub.com
    European Commission grants Approval of Venclyxto® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy. – Lymphoma Hub
    Read More
  • Sep 27, 2018 lymphomahub.com
    Treatment of adult HTLV-1 related T-cell leukemia/lymphoma – Lymphoma Hub
    Read More

Connect. Empower. Inspire.